Genmab — Oktober 2016
-
Vi røg da ned mod de 600 i februar. Helt skævt er det scenarie vel ikke ved en voldsom korrektion, hvor der trækkes store penge ud af markederne og hvor der under stor panik udløses en kaskade af stoploses.
-
Jeps. Det gør sandsynligheden mindre.
-
Når man har oplevet en finanskrise og set hvordan markedet i en periode var fuldstændig ligeglad med potentiale og fundamentale i de enkelte aktier, så ved man, at intet er umuligt ved en dyb generel korrektion. Det er vist det McJean lufter her i tråden.
-
Genmab (Buy)
We close in on a busy couple of months with the CMD in November and the ASH conference in December, which we believe could drive the share price higher. Our key focus is on longer-term data from the CASTOR and POLLUX studies and the dive deeper into the mechanism of actions of daratumumab, which could possibly become key ASH presentations. -
AB snuppede lige 21.000 netto i lukkeaktionen
god aften
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind